Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten research firms that are covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.6667.
CMPX has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a report on Monday, April 21st. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. Guggenheim cut their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, D. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th.
View Our Latest Analysis on Compass Therapeutics
Compass Therapeutics Trading Down 2.2%
Shares of CMPX stock traded down $0.06 during trading hours on Tuesday, hitting $2.72. The company's stock had a trading volume of 275,473 shares, compared to its average volume of 1,369,971. The stock has a market cap of $375.85 million, a price-to-earnings ratio of -6.62 and a beta of 1.49. The business has a fifty day moving average of $2.70 and a 200-day moving average of $2.49. Compass Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.08.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). On average, equities analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Compass Therapeutics
A number of hedge funds have recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in Compass Therapeutics in the 1st quarter valued at approximately $57,000. Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter valued at $35,000. Price T Rowe Associates Inc. MD lifted its position in Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after purchasing an additional 11,326 shares during the period. Renaissance Technologies LLC lifted its position in Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after purchasing an additional 56,000 shares during the period. Finally, ProShare Advisors LLC boosted its stake in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after buying an additional 9,451 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Articles
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
